Navigation Links
Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
Date:2/17/2009

considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

                       - Financial Statements Follow -



          GENESIS PHARMACEUTICALS ENTERPRISES, INC. AND SUBSIDIARIES

       CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
                                 (UNAUDITED)

                       For the Three Months Ended   For the Six Months Ended
                              December 31,                 December 31,
                           2008          2007          2008          2007
    REVENUES:
      Sales            $32,944,809  $25,154,071    $60,265,493  $40,416,860
      Sales -
       related
       parties                  --    1,394,662        243,909    2,742,757
    TOTAL REVENUES      32,944,809   26,548,733     60,509,402   43,159,617

      Cost of sales      7,138,166    6,524,403     12,851,210   10,730,348
      Cost of sales
       - related
       parties                  --      292,040         54,493      676,209
    COST OF SALES        7,138,166    6,816,443     12,905,703   11,406,557

    GROSS PROFIT        25,806,643   19,732,290     47,603,699   31,753,060

    RESEARCH AND
     DEVELOPMENT
     EXPENSE             1,098,525      937,390      2,196,450    1,202,310

    SELLING,
     GENERAL AND
     ADMINISTRATI
'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
3. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
4. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. OmegaGenesis Announces Angiogenesis Application Collaboration
7. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
8. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
9. Cardiogenesis Reports Third Quarter 2008 Results
10. ThermoGenesis Presentation at Rodman & Renshaw Conference
11. Genesis Pharmaceuticals Launches New Corporate Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)... Dec. 17, 2014   Synageva BioPharma Corp. ... therapeutic products for rare disorders, announced today its presentation ... in San Francisco, CA. ... Executive Officer, will present on Monday, January 12, 2015, ... will be webcast live and may be accessed from ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... composting from open dumps across the developing world could ... according to researchers in India, writing today in the ... , These days we in the developing world are ... not everyone has a compost bin and not all ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... scheduled to participate in the UBS Global Life,Sciences Conference, ... New York. On Monday, September 24, 2007 at ... of Angiotech, will give a 25-minute,presentation. A link ...
... PALO ALTO, Calif., Sept. 19 Telik, Inc.,(Nasdaq: ... corporate,overview at the UBS Global Life Sciences Conference in ... p.m. Eastern time (9:30 a.m. Pacific,time). Telik,s presentation will ... the Telik website, http://www.telik.com, through October 3,2007. ...
Cached Biology Technology:Landfill mining reduces environmental impact of growing waste 2Angiotech to participate in UBS Global Life Sciences Conference 2Angiotech to participate in UBS Global Life Sciences Conference 3
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... may be an effective way to monitor changes in ... implications for measuring biodiversity as well, according to new ... University of Florida and colleagues in the open access ... statistical models to estimate two aspects of biodiversity in ...
... , , , , , , ... , , , ... Click here for more information. , , ... , , , , , ...
... the 21st century, the temperature in the Baltic Sea will ... time since 1850. If no action is taken to alleviate ... for the marine environment. "This is the first time ... models and individual factors combine to affect a specific region. ...
Cached Biology News:A whale with a distinctly human-like voice 2A whale with a distinctly human-like voice 3Climate change threatens marine environment in the Baltic Sea 2
... uses include large-scale colony-counting and plaque-lifting, microbial ... TM automated colony picking and gridding ... product number, created to easily match Cornings ... please order under the old Sigma-Aldrich number ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
BD BioCoat Laminin 150 mm Culture Dishes...
...
Biology Products: